CONGRESSMAN CARTER URGING MATTHEW STRAIT DEA TO ADVANCE MARIJUANA CLINICAL RESEARCH
MMJ International Holdings distinguishes itself by adhering strictly to federal regulations at every stage of its R&D process. Rather than cutting corners, the company ensures its FDA clinical trials for its proprietary soft gelatin capsule-blending THC, CBD, and other phytocannabinoids-meet the highest standards set by federal law. This commitment not only minimizes regulatory risks but also enhances MMJ's credibility with government agencies and leading healthcare institutions.
